Abstracts
1
Fundação Oswaldo Ramos -Hospital do Rim e Hipertensão, São Paulo, São Paulo, Brazil, 2 Hospital de Clínicas de Porto Alegre, São Paulo, São Paulo, Brazil, 3 Bristol-Myers Squibb S/A, São Paulo, São Paulo, Brazil, 4 New BD Assessoria Empresarial LTDA, São Paulo, São Paulo, Brazil, 5 Bristol-Myers Squibb Co, Wallingford, CT, USA OBJECTIVES: Immunosuppressive drugs (IS) are used in combination/schemes to achieve optimal regimen of immunosupression, increasing graft and recipient survival rates in post kidney transplant patients. The aim of this study is to determine immunosuppressant treatment patterns and associated costs in kidney transplant patients from the Brazilian National Transplant Program. METHODS: A review of the entire government administrative claim database (Outpatient Information System -SIA/ DATASUS) was conducted from 2005 to 2008, to determine yearly expenses (in 2008 USD) with each IS combination. In order to assess the dynamics of the combinations used, a subset of this population, all patients from 7 hospitals who underwent kidney transplantation in 2004, was followed from January 2005 to December 2007 to estimate calcineurin inhibitors (CNI) switching rate and treatment adherence in terms of 24-month medication possession ratio (MPR). RESULTS: Analysis of the entire database reveals that overall IS expenses in kidney transplant patients more than doubled, from US$62,429,359 in 2005 to US$126,874,381 in 2008 , mostly due to an increase in both treatment volume and costs from 2006 to 2007. From 2005 to 2007, monthly treatment volume increased 14.7% for cyclosporine and 62.9% for tacrolimus, whereas costs increased 3.2% for cyclosporine and 93.1% for tacrolimus. The highest financially impacting combination per CNI were tacrolimus plus mycophenolate sodium (US$37,329,606 in 2008) , and cyclosporine plus mycophenolate sodium (US$10,163,990 in 2008) . A total of 540 patients were eligible for the subpopulation analysis. CNI therapy switch rate, from tacrolimus to cyclosporine or vice-versa was 4.3% (n = 185). MPR for CNIs was 73.7% (n = 224; SD = 21.7%). CONCLUSIONS: From 2005 to 2008, IS drugs expenses in post kidney transplant patients substantially increased in Brazil. Low CNI switching rates suggests that de novo patients are the main target population for newer CNIs. The poor drug adherence detected is an important point of concern. 
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ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS FROM TWO LARGE CLAIMS DATABASES
PUK9 SEVEN YEAR TRENDS OF PHARMACY BENEFIT ERYTHROPOIESIS-STIMULATING AGENT UTILIZATION AND COST CONSIDERATIONS OF CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
Vekeman F 1 , Bailey RA 2 , Laliberté F 3 , Senbetta M 2 , McKenzie RS 2 , Lefebvre P 3 1 Analysis Group, Inc., Washington , DC, USA, 2 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 3 Groupe d'analyse, Ltée, Montreal, QC, Canada OBJECTIVES: This study compared drug utilization patterns and associated costs as well as dosing trends over time in patients with chronic kidney disease (CKD) not on dialysis receiving epoetin alfa (EPO) or darbepoetin alfa (DARB) through a pharmacy benefit. METHODS: An analysis of pharmacy claims between July 2002 and March 2009 from the Ingenix IMPACT database was conducted. Patients ≥18 years, newly initiated on erythropoiesis-stimulating agents (ESAs), with ≥1 claim for CKD, and ≥1 ESA pharmacy claim were included. Patients diagnosed with cancer, receiving chemotherapy or dialysis, or receiving both agents were excluded. Mean cumulative ESA dose was used to calculate drug cost (using 10/2009 wholesale acquisition cost) and dose ratio (Units EPO: mcg DARB). Average weighted weekly ESA dose was calculated during the treatment episode to assess ESA utilization trends over time. Multivariate analysis was also conducted. RESULTS: A total of 4,202 ESA-treated patients were identified (EPO 3, 111; DARB 1, 091) . EPO patients were slightly older (60.1 vs. 57.0, P < .001) with a higher Charlson Comorbidity Index (1.68 vs 1.44, P < .001). Mean [SD] cumulative dose was 219,060 [236, 830] Units for EPO and 818 [956] mcg for DARB, resulting in a dose ratio of 268:1 (Units EPO: mcg DARB). The corresponding drug cost was 28% higher for DARB than EPO ($3163 vs. $4039, P < .001). From 2002 to 2009, a decreasing trend was observed in semi-annual mean weekly doses of ESAs [EPO: 17,053 to 13,674 Units (25% decrease); DARB: 63 to 51 mcg (20% decrease)]. After adjusting for potential confounding factors, the DARB cost premium and the decreasing weekly ESA dosing trend over time remained significant. CONCLUSIONS: This study of CKD patients not on dialysis receiving ESAs through pharmacy benefits reported significantly higher drug costs in the DARB group compared with the EPO group and a decreasing ESA dosing trend during the 7-year study period.
PUK10 IMPROVED RESOURCE UTILIZATION OUTCOMES ASSOCIATED WITH PREDIALYSIS USE OF PARICALCITOL FOR SECONDARY HYPERPARATHYROIDISM (SHPT)
Marx S 1 , Frye CB 2 , Khan SS 1 , Harshaw Q 2 , Audhya P 1 , Deering K 2 , Sterz R 1 1 Abbott, Abbott Park, IL, USA, 2 EPI-Q, Inc., Oak Brook, IL, USA OBJECTIVES: The objective of this study is to evaluate hospitalizations, outpatient services and medication use in the first year of dialysis associated with pre-dialysis treatment with paricalcitol compared to no predialysis vitamin D receptor (VDR) activator use in chronic kidney disease (CKD) patients with SHPT. METHODS: A matched cohort analysis was conducted in 154 hemodialysis patients comparing utilization outcomes of predialysis use of paricalcitol compared to no VDR activator treatment, using the Medstat ™ administrative claims database from 2000-2007. Patients were matched using propensity scoring for age, gender, Charlson co-morbidity Index, and pre-index total costs. Multivariate models adjusted for age, gender,
